[ad_1]
This is Cipla’s second launch within the diagnostics house after Elifast ELISA Test Kit. In this collaboration, Cipla can be accountable for the advertising and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that can be manufactured by Premier Medical Corporation Private Limited.
The test is a rapid level-of-care nasopharyngeal swab test that immediately detects the presence or absence of coronavirus antigen within the affected person’s physique, producing outcomes inside 15-20 minutes. Only authorised labs are permitted by ICMR to conduct the rapid antigen testing. The test can be marketed beneath the model title ‘CIPtest’.
CIPtest is a dependable excessive-performing package that has been validated and authorized by ICMR. It is discovered to have specificity and sensitivity of 98.09 per cent and upto 75 per cent respectively. The test just isn’t solely rapid with a fast flip-round time, but additionally permits simple interpretation of outcomes with out the necessity of any extra instrument. Cipla’s expansive distribution community will assist in guaranteeing provide of kits throughout the nation.
(This story has not been edited by Newslivenation employees and is auto-generated from a syndicated feed.)